Z. Klippel

发表

A Randomized, Single‐Blind Study Evaluating the Effect of a Bone Pain Education Video on Reported Bone Pain in Patients with Breast Cancer Receiving Chemotherapy and Pegfilgrastim

C. Maxwell, P. K. Morrow, M. Reiner, 2018, Pain management nursing : official journal of the American Society of Pain Management Nurses.

A systematic literature review of the efficacy, effectiveness, and safety of filgrastim

G. Lyman, J. Crawford, T. Osslund, 2017, Supportive Care in Cancer.

Validation of Claims Algorithms for Progression to Metastatic Cancer in Patients with Breast, Non-small Cell Lung, and Colorectal Cancer

J. Simeone, B. Nordstrom, K. Fraeman, 2016, Front. Oncol..

A Phase III, Randomized, Double‐Blind, Placebo‐Controlled Trial of Pegfilgrastim in Patients Receiving First‐Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti‐VEGF Evaluation Study (PAVES)

P. Gibbs, J. Jassem, Y. Hotko, 2017, Clinical colorectal cancer.

Risk of Febrile Neutropenia Associated With Select Myelosuppressive Chemotherapy Regimens in a Large Community-Based Oncology Practice.

Su-Jau Yang, Leila Family, C. Chao, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma.

M. Dimopoulos, J. H. Lee, R. Hájek, 2019, Blood.

Randomized phase 3 study of carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible , NDMM patients Running title : KMP vs VMP for newly diagnosed multiple myeloma

M. Dimopoulos, J. H. Lee, P. Moreau, 2019 .

Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation

D. Coffey, P. Becker, A. Cowan, 2016, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

Phase 3 Study (CLARION) of Carfilzomib, Melphalan, Prednisone (KMP) v Bortezomib, Melphalan, Prednisone (VMP) in Newly Diagnosed Multiple Myeloma (NDMM)

M. Dimopoulos, J. Miguel, J. H. Lee, 2017 .

E ﬃ cacy and safety of car ﬁ lzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma

M. Dimopoulos, Shaji K. Kumar, S. Bringhen, 2020 .

Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma.

R. Rifkin, J. Berenson, J. Shah, 2019, Clinical lymphoma, myeloma & leukemia.

Utilization of stored autologous PBSCs to support second autologous transplantation in multiple myeloma patients in the era of novel agent therapy

N. Burwick, P. Becker, W. Bensinger, 2015, Bone Marrow Transplantation.

Relationship between severity and duration of chemotherapy-induced neutropenia and risk of infection among patients with nonmyeloid malignancies

Hong Wang, J. Page, M. Reiner, 2016, Supportive Care in Cancer.

Immune escape from NY-ESO-1-specific T cell therapy via loss of heterozygosity in the MHC

E. Warren, P. Robbins, L. Voong, 2014, Gene Therapy.

Oprozomib, Pomalidomide, and Dexamethasone (OPomd) in Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): Initial Results of a Phase 1b Study (NCT01999335)

R. Rifkin, J. Berenson, J. Shah, 2015 .

A Study of Novel Febrile Neutropenia Risk Factors Related to Bone Marrow or Immune Suppression, Barrier Function, and Bacterial Flora.

Leila Family, C. Chao, Lie-Hong Chen, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)

M. Dimopoulos, D. Siegel, X. Leleu, 2019 .

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study

M. Dimopoulos, X. Leleu, O. Landgren, 2020, The Lancet.

Carfilzomib as salvage therapy in Waldenstrom macroglobulinemia: a case series

D. Siegel, D. Vesole, J. Richter, 2018, Leukemia & lymphoma.

Value of incorporating newly identified risk factors into risk prediction for chemotherapy‐induced febrile neutropenia

Leila Family, C. Chao, Lanfang Xu, 2018, Cancer medicine.

Trajectory of absolute neutrophil counts in patients treated with pegfilgrastim on the day of chemotherapy versus the day after chemotherapy

Hong Wang, J. Page, M. Reiner, 2016, Cancer Chemotherapy and Pharmacology.

Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma.

M. Dimopoulos, D. Siegel, Shaji K. Kumar, 2020, Blood advances.

In response to: Treatment of patients with multiple myeloma progressing on frontline therapy with lenalidomide, Moreau et al., 2019

C. Tekle, A. Kimball, Z. Klippel, 2019, Blood Cancer Journal.

Value of Incorporating Newly Identified Risk Factors into Risk Prediction for Chemotherapy-Induced Febrile Neutropenia (FN)

Leila Family, C. Chao, Lanfang Xu, 2016 .

Risk factors for febrile neutropenia in cancer patients treated with chemotherapy.

Leila Family, C. Chao, Lie-Hong Chen, 2016 .

Once‐weekly (70 mg/m2) vs twice‐weekly (56 mg/m2) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION‐1 trials

M. Dimopoulos, D. Siegel, R. Orlowski, 2020, Cancer medicine.